RU2006126828A - Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза - Google Patents
Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза Download PDFInfo
- Publication number
- RU2006126828A RU2006126828A RU2006126828/15A RU2006126828A RU2006126828A RU 2006126828 A RU2006126828 A RU 2006126828A RU 2006126828/15 A RU2006126828/15 A RU 2006126828/15A RU 2006126828 A RU2006126828 A RU 2006126828A RU 2006126828 A RU2006126828 A RU 2006126828A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- salt
- pharmaceutically acceptable
- prodrug
- acceptable salt
- Prior art date
Links
- 0 *c1ccc(*)c(CNC2C(C(c3ccccc3)c3ccccc3)N3CCC2CC3)c1 Chemical compound *c1ccc(*)c(CNC2C(C(c3ccccc3)c3ccccc3)N3CCC2CC3)c1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Anesthesiology (AREA)
- Surgery (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Способ улучшения качества выхода из наркоза путем снижения чрезмерной вокализации и/или бессмысленного движения, включающий стадию введения нуждающемуся в такой обработке животному терапевтически эффективного количества фармацевтической композиции антагониста рецептора NK-1 (нейрокинин-1), его фармацевтически приемлемой соли, пролекарства указанного соединения или указанной соли, или сольвата или гидрата указанного соединения, указанной соли или указанного пролекарства.
2. Применение антагониста рецептора NK-1, его фармацевтически приемлемой соли, пролекарства указанного соединения или указанной соли, или сольвата или гидрата указанного соединения, указанной соли или указанного пролекарства в изготовлении лекарства для улучшения качества выхода из наркоза путем снижения чрезмерной вокализации и/или бессмысленного движения.
3. Способ или применение по п.1 или 2, где антагонист рецептора NK-1 представляет собой соединение формулы I
где R2 выбран из группы, состоящей из метила, этила, изопропила, втор-бутила и трет-бутила, или его фармацевтически приемлемую соль.
4. Способ или применение по п.3, где соединение формулы I представляет собой соединение формулы Ia
(2S,3S)-2-бензгидрил-N-(5-трет-бутил-2-метоксибензил)хинуклидин-3-амин, или его фармацевтически приемлемую соль.
5. Способ или применение по п.4, где соединение представляет собой цитратную соль соединения формулы Ia.
6. Способ или применение по п.1 или 2, где композицию вводят парентерально, энтерально или перорально до, во время или после введения общего наркоза.
7. Способ или применение по п.6, где композицию вводят парентерально.
8. Способ или применение по п.7, где композиция дополнительно содержит фармацевтически приемлемый циклодекстрин.
9. Способ или применение по п.7 или 8, где количество антагониста NK-1 составляет от 0,01 до 100 мг/кг массы тела пациента.
10. Фармацевтическая композиция для улучшения качества выхода из наркоза путем снижения чрезмерной вокализации и/или бессмысленного движения, содержащая антагонист рецептора NK-1, его фармацевтически приемлемую соль, пролекарство указанного соединения или указанной соли, или сольват или гидрат указанного соединения, указанной соли или указанного пролекарства.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54069704P | 2004-01-30 | 2004-01-30 | |
| US60/540,697 | 2004-01-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006126828A true RU2006126828A (ru) | 2008-03-10 |
| RU2337685C2 RU2337685C2 (ru) | 2008-11-10 |
Family
ID=34910695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006126828/15A RU2337685C2 (ru) | 2004-01-30 | 2005-01-06 | Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20070155782A1 (ru) |
| EP (1) | EP1713479A1 (ru) |
| JP (1) | JP2007519701A (ru) |
| KR (1) | KR100880391B1 (ru) |
| CN (1) | CN1913893A (ru) |
| AU (1) | AU2005216706B2 (ru) |
| BR (1) | BRPI0507325A (ru) |
| CA (1) | CA2554823A1 (ru) |
| IL (1) | IL176830A0 (ru) |
| MX (1) | MXPA06007964A (ru) |
| NO (1) | NO20062965L (ru) |
| RU (1) | RU2337685C2 (ru) |
| WO (1) | WO2005082366A1 (ru) |
| ZA (1) | ZA200605149B (ru) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0506496B8 (pt) | 2004-01-30 | 2022-09-20 | Pfizer Prod Inc | composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese composição farmacêutica com tolerância melhorada no local de injeção compreendendo sulfobutiléter-ß-ciclodextrina e seu uso no tratamento de êmese |
| US9446029B2 (en) | 2010-07-27 | 2016-09-20 | Colorado State University Research Foundation | Use of NK-1 receptor antagonists in management of visceral pain |
| RU2489765C1 (ru) * | 2012-01-10 | 2013-08-10 | Открытое акционерное общество "Научно-исследовательский институт газоразрядных приборов "Плазма" (ОАО "Плазма") | Способ изготовления газонаполненного разрядника |
| CN114984223B (zh) * | 2022-05-31 | 2023-06-20 | 中国人民解放军陆军军医大学第二附属医院 | 生长激素促分泌素受体拮抗剂在制备吸入麻醉复苏制剂中的应用 |
| AT527172A1 (de) * | 2023-04-25 | 2024-11-15 | Vetviva Richter Gmbh | Maropitantformulierung |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US540644A (en) | 1895-06-11 | del yalle | ||
| US540897A (en) | 1895-06-11 | Harold f | ||
| DE122006000066I2 (de) * | 1991-05-31 | 2007-12-06 | Pfizer | Chinuclidinderivate |
| US5393762A (en) | 1993-06-04 | 1995-02-28 | Pfizer Inc. | Pharmaceutical agents for treatment of emesis |
| US6255320B1 (en) * | 1999-06-01 | 2001-07-03 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions |
| JP2005504029A (ja) | 2001-07-20 | 2005-02-10 | ファイザー・プロダクツ・インク | 犬の好ましくない行動を改善するためのｎｋ−１受容体アンタゴニストの使用 |
-
2005
- 2005-01-06 WO PCT/IB2005/000010 patent/WO2005082366A1/en active Application Filing
- 2005-01-06 RU RU2006126828/15A patent/RU2337685C2/ru not_active IP Right Cessation
- 2005-01-06 KR KR1020067015267A patent/KR100880391B1/ko not_active Expired - Fee Related
- 2005-01-06 BR BRPI0507325-1A patent/BRPI0507325A/pt not_active IP Right Cessation
- 2005-01-06 CA CA002554823A patent/CA2554823A1/en not_active Abandoned
- 2005-01-06 AU AU2005216706A patent/AU2005216706B2/en not_active Ceased
- 2005-01-06 US US10/587,590 patent/US20070155782A1/en not_active Abandoned
- 2005-01-06 EP EP05702181A patent/EP1713479A1/en not_active Withdrawn
- 2005-01-06 CN CNA2005800036680A patent/CN1913893A/zh active Pending
- 2005-01-06 MX MXPA06007964A patent/MXPA06007964A/es not_active Application Discontinuation
- 2005-01-06 JP JP2006550323A patent/JP2007519701A/ja not_active Withdrawn
-
2006
- 2006-06-22 ZA ZA200605149A patent/ZA200605149B/en unknown
- 2006-06-26 NO NO20062965A patent/NO20062965L/no not_active Application Discontinuation
- 2006-07-13 IL IL176830A patent/IL176830A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060127934A (ko) | 2006-12-13 |
| AU2005216706B2 (en) | 2007-11-29 |
| WO2005082366A1 (en) | 2005-09-09 |
| IL176830A0 (en) | 2006-10-31 |
| US20070155782A1 (en) | 2007-07-05 |
| EP1713479A1 (en) | 2006-10-25 |
| BRPI0507325A (pt) | 2007-07-03 |
| WO2005082366A8 (en) | 2005-12-15 |
| ZA200605149B (en) | 2007-11-28 |
| JP2007519701A (ja) | 2007-07-19 |
| RU2337685C2 (ru) | 2008-11-10 |
| AU2005216706A1 (en) | 2005-09-09 |
| MXPA06007964A (es) | 2007-01-26 |
| CA2554823A1 (en) | 2005-09-09 |
| NO20062965L (no) | 2006-07-21 |
| CN1913893A (zh) | 2007-02-14 |
| KR100880391B1 (ko) | 2009-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004538259A5 (ru) | ||
| CN1711085A (zh) | 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 | |
| JP2009526821A (ja) | 注意欠陥多動性障害治療用の新規な医薬組成物 | |
| JP2010077141A5 (ru) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2005508337A5 (ru) | ||
| JP2019515884A5 (ru) | ||
| JP2010522714A (ja) | 新規な医薬組成物 | |
| RU2008112181A (ru) | Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3 | |
| JP2013523600A (ja) | 統合失調症および関連疾患の治療方法 | |
| JP2006516643A5 (ru) | ||
| RU2006126828A (ru) | Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза | |
| JP2022508217A (ja) | Ｔａｓｋ－１およびｔａｓｋ－３チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用 | |
| JPH0637389B2 (ja) | 頻尿治療剤 | |
| RU2275906C2 (ru) | Средство для лечения болезни паркинсона, включающее в качестве активного ингредиента соединение, улучшающее астроцитную функцию | |
| JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| JP2022524819A (ja) | カプシド集合調節剤固体製剤 | |
| BR112013000164B1 (pt) | Agente terapêutico ou agente profilático | |
| JP2002536442A5 (ru) | ||
| JP2007519701A5 (ru) | ||
| JP2010536827A (ja) | ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体 | |
| JPWO2021188417A5 (ru) | ||
| JPWO2020037152A5 (ru) | ||
| JP2009501205A (ja) | 精神病治療用組成物 | |
| JP4598674B2 (ja) | 統合失調症治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100107 |